What Can We Learn from Fragment Based Optimization Programs? Gyorgy Keseru, Hungarian Academy of Sciences, speaking at Drug Discovery and Development 2014
Enabling New Pharma: Drug Re-purposing Efforts Go Mainstream. Innovative Alternatives for Stalled Pharmaceutical Pipelines Rathnam Chaguturu, SRI International, speaking at Drug Discovery and Development 2014
Rising Role of Academic Drug Discovery Barbara Slusher, Johns Hopkins University School of Medicine, speaking at Drug Discovery and Development 2014.
Science for Life Laboratory Drug Discovery & Development Platform Per Arvidson, Karolinska Institute, speaking at Drug Discovery and Development 2014
3D Organotypic Liver Cultures and their Application in Predictive Toxicology Fozia Noor, Saarland University, speaking at Advances in cellular Assays & Cell Culture 2014
Combining Computational Biology and High Content Imaging Approaches for Understanding DNA Damage and Repair Thierry Dorval, AstraZeneca, speaking at High Content Analysis 2014
Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines Christine Dufes, University of Strathclyde, speaking at Nanomedicine 2014.
Nanomedicines to Improve the Therapeutic Index of Drugs in Modern Drug Design Marianne Ashford, AstraZeneca, speaking at Nanomedicine 2014.
Using In vitro and In vivo Models to Assess the Local and Systemic Responses to Nanomaterial Exposure Vicki Stone, Heriot-Watt University, speaking at Nanomedicine 2014.